Incorporating these tools in clinical practice has profoundly changed the decision-making for adjuvant chemotherapy for patients with ER+/HER2- early breast cancer and the results from large prospective adjuvant trials have strengthened the clinical utility of multigene assays in this setting. This evidence concerns the gene ERBB2 and breast carcinoma.